The $100 bil­lion club gets a shake­up, dri­ven by biotech’s new blue-chip names

The drug in­dus­try of­fi­cial­ly has two new heavy­weights.

For the first time, Re­gen­eron and Ver­tex have crossed the $100 bil­lion mar­ket cap thresh­old. They join …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER